Nowadays, L-asparaginase derived from E. coli has been applied as first-line therapy and L-asparaginase derived from Erwinia chrysanthemi has been used for the treatment of ALL patients when hypersensitivity to E. coli-derived L-asparaginase happens (Keating, 2013). This evidence concerns the gene ASPG and acute lymphoblastic leukemia.